DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

Previous bird flu outbreaks and decades-old public health infrastructure have led industry to protect the hens used for ...

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump ...

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...

Following similar deals in countries like the United States and the U.K., Canada is bolstering its stockpile of bird flu ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...

CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company specializing in mRNA-based therapies and vaccines with a market ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

It’s a problem that’s been hovering since the 2017 Dengvaxia controversy led to the suspension of the Department of Health’s (DOH) vaccination campaign against this endemic scourge. On ...